Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Apr;59(4):631–635. doi: 10.1038/bjc.1989.128

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.

G B Zulian 1, P Selby 1, S Milan 1, A Nandi 1, M Gore 1, G Forgeson 1, T J Perren 1, T J McElwain 1
PMCID: PMC2247129  PMID: 2653400

Abstract

Thirty-eight patients with previously treated Hodgkin's disease were given high dose combination chemotherapy using melphalan and BCNU and autologous bone marrow transplantation. In 25 patients etoposide was added in conventional dosage. During the course of the study the dose of melphalan was increased from 80 to 140 mg m-2 and the dose of BCNU from 300 to 600 mg m-2. The response rate was 76% with 53% complete remission. Forty-five per cent of the patients are free of disease at 4-20 months follow-up. There were eight (26%) treatment-related deaths due to lung damage (seven cases) and irreversible cardiac failure (one case). Fatal lung damage occurred only in patients receiving 600 mg m-2 of BCNU with high dose melphalan. The dose of BCNU given with high dose melphalan should not exceed 500 mg m-2. This treatment is effective against relapsed Hodgkin's disease but must be used cautiously. The best time for its use remains to be determined.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Canellos G. P. Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous. J Clin Oncol. 1985 Nov;3(11):1451–1454. doi: 10.1200/JCO.1985.3.11.1451. [DOI] [PubMed] [Google Scholar]
  2. Fox K. A., Lippman S. M., Cassady J. R., Heusinkveld R. S., Miller T. P. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol. 1987 Jan;5(1):38–45. doi: 10.1200/JCO.1987.5.1.38. [DOI] [PubMed] [Google Scholar]
  3. Hagemeister F. B., Tannir N., McLaughlin P., Salvador P., Riggs S., Velasquez W. S., Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987 Apr;5(4):556–561. doi: 10.1200/JCO.1987.5.4.556. [DOI] [PubMed] [Google Scholar]
  4. Harver A., Tenney S. M., Baird J. C. A cautionary note on the interpretation of the power law for respiratory effort. Am Rev Respir Dis. 1986 Feb;133(2):341–342. doi: 10.1164/arrd.1986.133.2.341. [DOI] [PubMed] [Google Scholar]
  5. McElwain T. J., Powles R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983 Oct 8;2(8354):822–824. doi: 10.1016/s0140-6736(83)90739-0. [DOI] [PubMed] [Google Scholar]
  6. Philip T., Dumont J., Teillet F., Maraninchi D., Gorin N. C., Kuentz M., Harousseau J. L., Marty M., Pinkerton R., Herve P. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br J Cancer. 1986 Jun;53(6):737–742. doi: 10.1038/bjc.1986.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Roach M., 3rd, Kapp D. S., Rosenberg S. A., Hoppe R. T. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol. 1987 Apr;5(4):550–555. doi: 10.1200/JCO.1987.5.4.550. [DOI] [PubMed] [Google Scholar]
  8. Taylor R. E., McElwain T. J., Barrett A., Peckham M. J. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother Pharmacol. 1982;7(2-3):175–177. doi: 10.1007/BF00254543. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES